PIK3CA and breast carcinoma: PIK3CA molecular testing has rapidly emerged as a new clinical request at the sight of data from the SOLAR-1 study regarding the efficacy of alpelisib in combination with fulvestrant in patients with advanced HR+/HER2− breast cancer previously treated with endocrine therapy [2,14].